The U.S. Food and Drug Administration (FDA) has approved application number ANDA086746 submitted by Lederle. The approval pertains to an oral tablet formulation of amitriptyline hydrochloride at a strength of 25 mg. The product is identified as "AMITRIPTYLINE HYDROCHLORIDE" with a product number 001 and is currently marked as discontinued.
The submission was classified as a supplemental (SUPPL) filing, submission number 2, with a status of AP (approved). It falls under the manufacturing (CMC) category, with the submission status date recorded as March 15, 1982.
No reference drug or reference standard was indicated for this product.
Actualités réglementaires25 août 2026•1 min de lecture
FDA Approves ANDA086746 for Amitriptyline Tablet – Lederle
1
FDA approved application ANDA086746 for an oral amitriptyline hydrochloride 25 mg tablet submitted by Lederle; the product is listed as discontinued.
Compilé par l'équipe PharmaCountry · Source : FDA.gov
Évaluations
(0)
(0)
(0)
(0)
(0)
Plus d'articles
Voir tous les articlesRecherches & Rapports
Global Finished Dosage Manufacturing Landscape 2026
5 oct. 2026
Actualités réglementairesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept. 2026
Laissez votre note